Jonathan Wolleben
Stock Analyst at Citizens JMP
(4.90)
# 270
Out of 4,712 analysts
699
Total ratings
54%
Success rate
24%
Average return
Main Sectors:
Stocks Rated by Jonathan Wolleben
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHVS Pharvaris | Reiterated: Buy | $74 → $79 | $37.74 | +109.33% | 35 | Sep 9, 2026 | |
| PTGX Protagonist Therapeutics | Reiterated: Buy | $165 → $170 | $145.09 | +17.17% | 38 | Aug 31, 2026 | |
| SION Sionna Therapeutics | Downgraded: Hold | n/a | $7.48 | - | 2 | Aug 10, 2026 | |
| GPCR Structure Therapeutics | Reiterated: Buy | $113 → $110 | $41.23 | +166.80% | 26 | Aug 7, 2026 | |
| BMEA Biomea Fusion | Reiterated: Buy | $9 → $7 | $1.85 | +279.40% | 2 | Aug 6, 2026 | |
| MIRM Mirum Pharmaceuticals | Reiterated: Buy | $146 → $137 | $98.30 | +39.37% | 33 | Aug 6, 2026 | |
| RYTM Rhythm Pharmaceuticals | Reiterated: Buy | $152 → $160 | $101.06 | +58.32% | 22 | Aug 5, 2026 | |
| ANNX Annexon | Initiated Coverage: Sell | $3 | $4.37 | -31.35% | 1 | Jul 21, 2026 | |
| MDGL Madrigal Pharmaceuticals | Reiterated: Buy | $745 → $739 | $546.66 | +35.18% | 62 | Jul 17, 2026 | |
| DBVT DBV Technologies | Reiterated: Buy | $55 | $13.44 | +309.23% | 45 | Jun 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 → $12 | $10.86 | +10.50% | 21 | May 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 → $11 | $3.35 | +228.36% | 81 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $170 → $150 | $55.74 | +169.11% | 28 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 → $11 | $5.73 | +91.97% | 2 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $26 → $25 | $3.47 | +620.46% | 3 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $61 → $86 | $62.91 | +36.70% | 4 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 → $28 | $8.81 | +218.00% | 49 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $1.99 | +302.01% | 42 | Mar 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $11.47 | - | 63 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $30.32 | - | 5 | Jan 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 → $11 | $5.42 | +103.14% | 17 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $3.87 | +365.12% | 41 | Oct 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $120 → $32 | $2.23 | +1,334.98% | 7 | Oct 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 | $7.20 | n/a | 27 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $16.97 | n/a | 42 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $24 | $28.16 | n/a | 1 | May 12, 2023 |
Pharvaris
Sep 9, 2026
Reiterated: Buy
Price Target: $74 → $79
Current: $37.74
Upside: +109.33%
Protagonist Therapeutics
Aug 31, 2026
Reiterated: Buy
Price Target: $165 → $170
Current: $145.09
Upside: +17.17%
Sionna Therapeutics
Aug 10, 2026
Downgraded: Hold
Price Target: n/a
Current: $7.48
Upside: -
Structure Therapeutics
Aug 7, 2026
Reiterated: Buy
Price Target: $113 → $110
Current: $41.23
Upside: +166.80%
Biomea Fusion
Aug 6, 2026
Reiterated: Buy
Price Target: $9 → $7
Current: $1.85
Upside: +279.40%
Mirum Pharmaceuticals
Aug 6, 2026
Reiterated: Buy
Price Target: $146 → $137
Current: $98.30
Upside: +39.37%
Rhythm Pharmaceuticals
Aug 5, 2026
Reiterated: Buy
Price Target: $152 → $160
Current: $101.06
Upside: +58.32%
Annexon
Jul 21, 2026
Initiated Coverage: Sell
Price Target: $3
Current: $4.37
Upside: -31.35%
Madrigal Pharmaceuticals
Jul 17, 2026
Reiterated: Buy
Price Target: $745 → $739
Current: $546.66
Upside: +35.18%
DBV Technologies
Jun 30, 2026
Reiterated: Buy
Price Target: $55
Current: $13.44
Upside: +309.23%
May 19, 2026
Reiterated: Buy
Price Target: $35 → $12
Current: $10.86
Upside: +10.50%
May 14, 2026
Reiterated: Buy
Price Target: $14 → $11
Current: $3.35
Upside: +228.36%
May 14, 2026
Reiterated: Buy
Price Target: $170 → $150
Current: $55.74
Upside: +169.11%
May 13, 2026
Reiterated: Buy
Price Target: $12 → $11
Current: $5.73
Upside: +91.97%
May 13, 2026
Reiterated: Buy
Price Target: $26 → $25
Current: $3.47
Upside: +620.46%
May 12, 2026
Reiterated: Buy
Price Target: $61 → $86
Current: $62.91
Upside: +36.70%
May 7, 2026
Reiterated: Buy
Price Target: $25 → $28
Current: $8.81
Upside: +218.00%
Mar 12, 2026
Reiterated: Buy
Price Target: $8
Current: $1.99
Upside: +302.01%
Feb 17, 2026
Reiterated: Buy
Price Target: n/a
Current: $11.47
Upside: -
Jan 29, 2026
Downgraded: Hold
Price Target: n/a
Current: $30.32
Upside: -
Oct 23, 2025
Reiterated: Buy
Price Target: $8 → $11
Current: $5.42
Upside: +103.14%
Oct 6, 2025
Reiterated: Buy
Price Target: $18
Current: $3.87
Upside: +365.12%
Oct 6, 2025
Reiterated: Buy
Price Target: $120 → $32
Current: $2.23
Upside: +1,334.98%
May 23, 2025
Reiterated: Buy
Price Target: $19
Current: $7.20
Upside: n/a
Apr 23, 2025
Reiterated: Hold
Price Target: n/a
Current: $16.97
Upside: n/a
May 12, 2023
Reiterated: Buy
Price Target: $24
Current: $28.16
Upside: n/a